PubRank

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

Clinical Trial ID NCT01067287

PubWeight™ 21.47‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01067287

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
2 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
3 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
4 Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011 1.16
5 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
6 Promising therapies in multiple myeloma. Blood 2015 0.89
7 Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant 2015 0.89
8 Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol 2012 0.88
9 Enhancement of dendritic cells as vaccines for cancer. Immunotherapy 2010 0.86
10 Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta 2015 0.86
11 Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med 2014 0.85
12 Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol 2015 0.82
13 Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci 2016 0.82
14 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
15 The development of potential antibody-based therapies for myeloma. Blood Rev 2014 0.81
16 Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma. J Cell Biochem 2016 0.78
17 Immunotherapeutic approaches to treat multiple myeloma. Hum Vaccin Immunother 2013 0.77
18 The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals (Basel) 2016 0.77
19 A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer 2015 0.76
20 Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. J Mol Med (Berl) 2015 0.75
21 Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. Rare Cancers Ther 2015 0.75
Next 100